Claims for Patent: 5,663,483

Summary for Patent: 5,663,483

Title:	Transgenic mice expressing human cholesterol 7.alpha.hydroxylase
Abstract:	Genomic DNA of cholesterol 7.alpha.-hydroxylase and a minigene are disclosed. The minigene is used for making a transgenic animal that produces functionally active cholesterol 7.alpha.-hydroxylase and functions as a disease model. A cholesterol 7.alpha.-hydroxylase promoter region and reporter gene construct is provided, as well as a transgenic animal that expresses the promoter/reporter gene.
Inventor(s):	Chiang; John Young Ling (Stow, OH)
Assignee:	Northeastern Ohio Universities College of Medicine (Rootstown, OH)
Application Number:	08/361,458
Patent Claims:	1. A method of making a transgenic mouse that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse comprising the steps of: (A) microinjecting a fertilized oocyte of a mouse with a human CYP7 minigene construct comprising a promoter region operably linked to CYP7 nucleotide fragments comprising exon I, intron I, exon II, intron II, exon III, exon IV, exon V, and exon VI, and (B) detecting expression of human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue of a mouse generated from said fertilized oocyte. 2. A method according to claim 1, wherein said minigene construct further comprises a partial intron IV. 3. A method according to claim 2, wherein said minigene construct further comprises intron V. 4. A method according to claim 1, wherein said promoter region of said minigene construct is a promoter sequence obtained from a 5.5 kb sequenced fragment of .lambda.HG7.alpha.26 (ATCC 75534). 5. A transgenic mouse made by the method of claim 1 that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse. 6. A progeny of the mouse of claim 5 that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse. 7. A germ cell of the mouse of claim 5 that is capable of producing a transgenic mouse that expressed human cholesterol 7.alpha.-hydroxlase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse. 8. A transgenic mouse which expresses human cholesterol 7.alpha.-hydroxylase (CYP7), wherein said human CYP7 is expressed in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse. 9. A progeny of the mouse of claim 8 that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse. 10. A germ cell of the mouse of claim 8 that is capable of producing a transgenic mouse that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

Details for Patent 5,663,483

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2014-09-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2014-09-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2014-09-02